ADDEX THERAPEUTICS LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1155 CHF | +0.43% |
|
-23.26% | +151.09% |
| 04-24 | Top Premarket Decliners | MT |
| 04-18 | Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 43.44 | 53.24 | 39.42 | 10.39 | 6.181 | 14.81 | - |
| Enterprise Value (EV) 1 | 12.06 | 34.48 | 19.4 | 3.801 | 6.181 | 14.45 | 7.587 |
| P/E ratio | -2.93 x | -4.15 x | -2.31 x | -0.22 x | -0.33 x | -1.28 x | 2.1 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.7 x | 13.7 x | 12.5 x | 7.19 x | 3.75 x | - | 1.38 x |
| EV / Revenue | 4.37 x | 8.89 x | 6.15 x | 2.63 x | 3.75 x | - | 0.71 x |
| EV / EBITDA | -0.85 x | -2.91 x | -1.28 x | -0.19 x | - | -1.96 x | 30.3 x |
| EV / FCF | -1.27 x | -2.82 x | -1.32 x | -0.23 x | - | -2.29 x | 0.55 x |
| FCF Yield | -78.8% | -35.5% | -76% | -432% | - | -43.6% | 181% |
| Price to Book | 1.71 x | 3.69 x | 2.33 x | 1.58 x | - | 3.85 x | 0.89 x |
| Nbr of stocks (in thousands) | 26,485 | 26,754 | 37,903 | 103,234 | 134,374 | 128,257 | - |
| Reference price 2 | 1.640 | 1.990 | 1.040 | 0.1006 | 0.0460 | 0.1155 | 0.1155 |
| Announcement Date | 20-04-08 | 21-03-11 | 22-03-10 | 23-03-30 | 24-04-18 | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.763 | 3.879 | 3.153 | 1.445 | 1.647 | - | 10.75 |
| EBITDA 1 | -14.27 | -11.86 | -15.16 | -20.2 | - | -7.392 | 0.25 |
| EBIT 1 | -14.6 | -12.24 | -15.51 | -20.52 | -10.28 | -7.392 | 0.21 |
| Operating Margin | -528.56% | -315.62% | -491.79% | -1,420.07% | -624.23% | - | 1.95% |
| Earnings before Tax (EBT) 1 | -14.78 | -12.86 | -15.35 | -20.8 | -10.56 | -6.3 | 0.05 |
| Net income 1 | -14.78 | -12.86 | -15.35 | -20.8 | -10.56 | -6.3 | 0.05 |
| Net margin | -534.96% | -331.5% | -486.9% | -1,439.72% | -640.92% | - | 0.47% |
| EPS 2 | -0.5600 | -0.4800 | -0.4500 | -0.4600 | -0.1400 | -0.0900 | 0.0550 |
| Free Cash Flow 1 | -9.511 | -12.24 | -14.74 | -16.44 | - | -6.3 | 13.7 |
| FCF margin | -344.21% | -315.53% | -467.39% | -1,137.56% | - | - | 127.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 5,480% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 27,400% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 20-04-08 | 21-03-11 | 22-03-10 | 23-03-30 | 24-04-18 | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.7578 | 0.4009 | 0.244 | 0.186 | 0.4157 | - | 0.329 | 0.1534 | 0.7 | 0.7 | 0.7 | 0.7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | -3.576 | -4.275 | -5.763 | -7.092 | -4.167 | - | -2.652 | -2.682 | - | - | - | - |
| Operating Margin | -471.9% | -1,066.3% | -2,361.89% | -3,812.9% | -1,002.4% | - | -806.08% | -1,748.07% | - | - | - | - |
| Earnings before Tax (EBT) | -3.598 | -4.424 | -5.824 | -7.221 | -4.108 | - | -2.617 | -2.857 | - | - | - | - |
| Net income | -3.598 | -4.424 | -5.824 | -7.221 | -4.108 | -2.675 | -2.617 | -2.857 | - | - | - | - |
| Net margin | -474.81% | -1,103.46% | -2,386.89% | -3,882.26% | -988.12% | - | -795.44% | -1,861.74% | - | - | - | - |
| EPS 2 | -0.1100 | -0.1300 | -0.1500 | -0.1900 | -0.0900 | -0.0400 | -0.0300 | -0.0300 | -0.0200 | -0.0200 | -0.0200 | -0.0200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-04 | 22-03-10 | 22-05-05 | 22-07-30 | 22-11-11 | 23-08-10 | 23-11-29 | 24-04-18 | - | - | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 31.4 | 18.8 | 20 | 6.58 | - | 0.36 | 7.23 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -9.51 | -12.2 | -14.7 | -16.4 | - | -6.3 | 13.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.9600 | 0.5400 | 0.4500 | 0.0600 | - | 0.0300 | 0.1300 |
| Cash Flow per Share | -0.3600 | -0.4600 | -0.4300 | - | - | - | - |
| Capex | - | 0.06 | 0.03 | 0 | - | - | - |
| Capex / Sales | - | 1.53% | 1% | 0.04% | - | - | - |
| Announcement Date | 20-04-08 | 21-03-11 | 22-03-10 | 23-03-30 | 24-04-18 | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.1155
CHF
Average target price
0.16
CHF
Spread / Average Target
+38.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +151.09% | 16.19M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ADXN Stock
- Financials Addex Therapeutics Ltd
